About the Malignant Fibrous Histiocytoma Session
Malignant fibrous histiocytoma (MFH), now termed undifferentiated pleomorphic sarcoma, is a rare soft tissue sarcoma characterized by aggressive growth and high metastatic potential. Research in this area focuses on understanding its molecular underpinnings and identifying targeted therapies. Recent studies delve into genomic profiling to unravel the genetic alterations driving MFH development, offering insights into potential therapeutic targets. Immunotherapy, particularly immune checkpoint inhibitors, emerges as a promising avenue, enhancing the body's immune response against MFH. Additionally, advancements in imaging techniques aid in early detection and accurate staging, optimizing treatment strategies. Collaborative efforts among researchers, clinicians, and patients drive progress toward improved outcomes for individuals battling this challenging cancer.
Topics Covered in Malignant Fibrous Histiocytoma
Current Nomenclature
Diagnosis of Exclusion
Complex Karyotypes
Limb-Sparing Surgery
Perioperative Radiotherapy
Checkpoint Inhibitors
Related Scientific Sessions at CIOC 2027
Why Attend the Malignant Fibrous Histiocytoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Malignant Fibrous Histiocytoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Malignant Fibrous Histiocytoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Malignant Fibrous Histiocytoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Malignant Fibrous Histiocytoma Conference 2027 — FAQs
What is the Malignant Fibrous Histiocytoma track at CIOC 2027?
The Malignant Fibrous Histiocytoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Malignant Fibrous Histiocytoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Malignant Fibrous Histiocytoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Malignant Fibrous Histiocytoma are all welcome — whether presenting or attending.
Can I present my research in the Malignant Fibrous Histiocytoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Malignant Fibrous Histiocytoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Malignant Fibrous Histiocytoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.